Analysis of the key themes driving M&A activity reveals that artificial intelligence accounted for 7 medical devices deals announced in Q3 2022, worth a total value of $3.7m, according to GlobalData’s whitepaper on Artificial Intelligence in Medical Devices – M&A Deal Activity in Q3 2022. The $2.9m acquisition of Pilloxa by iZafe Group was the industry’s largest disclosed deal.

In value terms, artificial intelligence-related deal activity decreased by 82% in Q3 2022 compared with the previous quarter’s total of $20m and fell by 98% as compared to Q3 2021. Related deal volume increased by 133% in Q3 2022 versus the previous quarter and was 22% lower than in Q3 2021.







                     
   




Top 5 M&A deals related to artificial intelligence in the medical devices industry since 2021
Target Acquirer Deal Value ($M) Deal Date
Preventice Boston Scientific $1,225M Jan-21
Decipher Biosciences Veracyte $600M Feb-21
Modern Fertility Roman Health Ventures $225M May-21
Inventive Healthcare Solutions; Virusight Diagnostic $111M Aug-21
Vicarious Surgical $102M Apr-21
Source: GlobalData Deals Database

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Acquisition, Asset transactions and Mergers.